[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zevra Therapeutics Inc (ZVRA)

Zevra Therapeutics Inc (ZVRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 826,428
  • Shares Outstanding, K 59,115
  • Annual Sales, $ 106,470 K
  • Annual Income, $ 83,230 K
  • EBIT $ 56 M
  • EBITDA $ 115 M
  • 60-Month Beta 0.85
  • Price/Sales 7.67
  • Price/Cash Flow 14.78
  • Price/Book 4.02

Options Overview Details

View History
  • Implied Volatility 83.16% (+23.01%)
  • Historical Volatility 65.78%
  • IV Percentile 25%
  • IV Rank 11.38%
  • IV High 339.85% on 03/03/26
  • IV Low 50.19% on 06/23/26
  • Expected Move (DTE 12) 0.41 (2.92%)
  • Put/Call Vol Ratio 0.56
  • Today's Volume 53
  • Volume Avg (30-Day) 1,181
  • Put/Call OI Ratio 0.90
  • Today's Open Interest 46,801
  • Open Int (30-Day) 52,340
  • Expected Range 13.57 to 14.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.08
  • Number of Estimates 3
  • High Estimate $0.10
  • Low Estimate $0.06
  • Prior Year $-0.06
  • Growth Rate Est. (year over year) +233.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.35 +35.01%
on 06/05/26
14.58 -4.12%
on 06/30/26
+3.10 (+28.49%)
since 06/02/26
3-Month
9.27 +50.74%
on 04/06/26
14.58 -4.12%
on 06/30/26
+4.58 (+48.72%)
since 04/02/26
52-Week
7.16 +95.25%
on 09/17/25
14.58 -4.12%
on 06/30/26
+4.57 (+48.57%)
since 07/02/25

Most Recent Stories

More News
Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)

BOSTON, June 23, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living...

ZVRA : 13.98 (+1.23%)
Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition

BOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living...

ZVRA : 13.98 (+1.23%)
Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA

MIPLYFFA  patent submitted for Orange Book listing, with patent protection to 2041 Separately filed patent term extension remains pending with the U.S. Patent and Trademark Office BOSTON, June...

ZVRA : 13.98 (+1.23%)
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living...

ZVRA : 13.98 (+1.23%)
Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease,...

ZVRA : 13.98 (+1.23%)
Zevra Therapeutics: Q1 Earnings Snapshot

Zevra Therapeutics: Q1 Earnings Snapshot

ZVRA : 13.98 (+1.23%)
Zevra Reports First Quarter 2026 Financial Results and Corporate Update

Q1 2026 net revenue of $36.2 million , a 78% increase over Q1 2025 Completed $50.0 million sale of SDX portfolio to Commave Therapeutics Operational execution fueled strong cash position...

ZVRA : 13.98 (+1.23%)
Zevra's Rare Disease Portfolio May Finally Have Enough Market Traction to Revalue

Barchart Research What to Expect from ZVRA Earnings ZVRA Generated May 5, 2026 Current Price $10.61 EPS Estimate $$0.06 Consensus Rating Strong Buy Average Move 7.85% Zevra's Rare Disease Portfolio May...

ZVRA : 13.98 (+1.23%)
Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call

BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease,...

ZVRA : 13.98 (+1.23%)
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease,...

ZVRA : 13.98 (+1.23%)

Business Summary

Zevra Therapeutics is a rare disease company melding science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. Zevra Therapeutics, formerly known as KemPharm Inc., is based in CELEBRATION, Fla.

See More

Key Turning Points

3rd Resistance Point 14.69
2nd Resistance Point 14.36
1st Resistance Point 14.17
Last Price 13.98
1st Support Level 13.66
2nd Support Level 13.33
3rd Support Level 13.14

See More

52-Week High 14.58
Last Price 13.98
Fibonacci 61.8% 11.75
Fibonacci 50% 10.87
Fibonacci 38.2% 9.99
52-Week Low 7.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.